文献速递心脑血管急症

急性冠脉综合征患者经皮冠状动脉介入治疗后6个月与12个月或更长双联抗血小板治疗的比较(SMART-DATE):一项随机、开放标签、非劣效性试验

6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial.
PubMed 文献 · Lancet · 2018-03-12
一句话结论在急性冠脉综合征接受经皮冠状动脉介入治疗的患者中,6个月双联抗血小板治疗相比12个月或更长疗程增加心肌梗死风险,且非劣效性界值宽,不能得出短期治疗安全的结论;作者认为无高出血风险者 prolonged DAPT 仍为标准治疗。

SMART-DATE 是一项在韩国31个中心进行的随机、开放标签、非劣效性试验,纳入2712例接受经皮冠状动脉介入治疗的急性冠脉综合征患者,随机分为6个月双联抗血小板治疗组(1357例)和12个月或更长双联抗血小板治疗组(1355例)。主要终点为18个月时全因死亡、心肌梗死或卒中的复合终点,6个月组累计事件率4.7% vs 12个月或更长组4.2%,绝对风险差0.5%,单侧95%CI上限1.8%,预设非劣效界值2.0%,P非劣效=0.03。心肌梗死发生率6个月组高于12个月或更长组(1.8% vs 0.8%,HR 2.41,95%CI 1.15-5.05,P=0.02)。作者结论认为,6个月双联抗血小板治疗增加心肌梗死风险且非劣效界值宽,不能认定短期治疗安全;无过高出血风险的患者延长双联抗血小板治疗仍为标准治疗。

要点

  • 在急性冠脉综合征经皮冠状动脉介入治疗患者中,6个月双联抗血小板治疗组18个月心肌梗死发生率1.8%(24例)高于12个月或更长组0.8%(10例),HR 2.41(95%CI 1.15-5.05),P=0.02。
  • 主要复合终点(全因死亡、心肌梗死或卒中)6个月组4.7% vs 12个月或更长组4.2%,绝对风险差0.5%,单侧95%CI上限1.8%,预设非劣效界值2.0%,P非劣效=0.03。
  • 全因死亡6个月组2.6%(35例)vs 12个月或更长组2.9%(39例),HR 0.90(95%CI 0.57-1.42),P=0.90,无显著差异;卒中0.8%(11例)vs 0.9%(12例),HR 0.92(95%CI 0.41-2.08),P=0.84,无显著差异。
  • BARC 2-5型出血6个月组2.7%(35例)vs 12个月或更长组3.9%(51例),HR 0.69(95%CI 0.45-1.05),P=0.09,无显著差异;支架内血栓1.1%(15例)vs 0.7%(10例),HR 1.50(95%CI 0.68-3.35),P=0.32,无显著差异。
  • 作者认为,6个月双联抗血小板治疗增加心肌梗死风险且非劣效界值宽,不能得出短期治疗安全的结论;无过高出血风险的急性冠脉综合征患者延长双联抗血小板治疗仍为标准治疗。

适用人群与场景

  • 纳入标准:不稳定型心绞痛、非ST段抬高型心肌梗死或ST段抬高型心肌梗死,并接受经皮冠状动脉介入治疗的患者。
  • 研究在韩国31个中心进行,随机分组时按中心、临床表现和糖尿病进行分层。

诊断标准与关键阈值

  • 主要终点为非劣效性检验,预设非劣效界值为2.0%。
  • 支架内血栓采用学术研究联盟(Academic Research Consortium)定义的确定或可能支架内血栓。
  • 出血采用出血学术研究联盟(Bleeding Academic Research Consortium,BARC)2-5型出血定义。

处置流程与药物剂量

  • 6个月双联抗血小板治疗组:阿司匹林加P2Y12抑制剂治疗6个月;其中79.7%(1082例)使用氯吡格雷作为P2Y12抑制剂。
  • 12个月或更长双联抗血小板治疗组:阿司匹林加P2Y12抑制剂治疗12个月或更长;其中81.8%(1109例)使用氯吡格雷作为P2Y12抑制剂。
  • 作者认为,无过高出血风险的急性冠脉综合征患者延长双联抗血小板治疗仍为标准治疗。

研究设计与关键结果

  • 研究类型:随机、开放标签、非劣效性试验;样本量2712例(6个月组1357例,12个月或更长组1355例);31个中心;人群为接受经皮冠状动脉介入治疗的急性冠脉综合征患者;干预为6个月双联抗血小板治疗 vs 12个月或更长双联抗血小板治疗。
  • 主要终点(18个月全因死亡、心肌梗死或卒中复合终点):6个月组63例,累计事件率4.7%;12个月或更长组56例,累计事件率4.2%;绝对风险差0.5%,单侧95%CI上限1.8%,P非劣效=0.03(预设非劣效界值2.0%)。
  • 心肌梗死:6个月组24例(1.8%)vs 12个月或更长组10例(0.8%),HR 2.41(95%CI 1.15-5.05),P=0.02。
  • 全因死亡:6个月组35例(2.6%)vs 12个月或更长组39例(2.9%),HR 0.90(95%CI 0.57-1.42),P=0.90,无显著差异;卒中:6个月组11例(0.8%)vs 12个月或更长组12例(0.9%),HR 0.92(95%CI 0.41-2.08),P=0.84,无显著差异。
  • 支架内血栓(确定或可能):6个月组15例(1.1%)vs 12个月或更长组10例(0.7%),HR 1.50(95%CI 0.68-3.35),P=0.32,无显著差异。
  • BARC 2-5型出血:6个月组35例(2.7%)vs 12个月或更长组51例(3.9%),HR 0.69(95%CI 0.45-1.05),P=0.09,无显著差异。
  • 符合方案分析结果与意向性治疗分析相似。

证据类型、等级与局限

  • 证据类型:随机、开放标签、非劣效性试验。
  • 作者结论:6个月双联抗血小板治疗增加心肌梗死风险且非劣效界值宽,不能得出短期治疗安全的结论;无过高出血风险的急性冠脉综合征患者延长双联抗血小板治疗仍为标准治疗。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于接受经皮冠状动脉介入治疗的急性冠脉综合征患者,6个月双联抗血小板治疗与12个月或更长治疗相比,心肌梗死发生率更高(1.8% vs 0.8%,HR 2.41,95%CI 1.15-5.05),作者认为不能得出短期治疗安全的结论。
  • 作者认为,无过高出血风险的急性冠脉综合征患者延长双联抗血小板治疗仍为标准治疗;对于出血风险过高者,原文未给出推荐。

指南或共识出处

  • SMART-DATE试验,注册号ClinicalTrials.gov NCT01701453,发表于Lancet。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Current guidelines recommend dual antiplatelet therapy (DAPT) of aspirin plus a P2Y12 inhibitor for at least 12 months after implantation of drug-eluting stents (DES) in patients with acute coronary syndrome. However, available data about the optimal duration of DAPT in patients with acute coronary syndrome undergoing percutaneous coronary intervention are scant. We aimed to investigate whether a 6-month duration of DAPT would be non-inferior to the conventional 12-month or longer duration of DAPT in this population.

METHODS: We did a randomised, open-label, non-inferiority trial at 31 centres in South Korea. Patients were eligible if they had unstable angina, non-ST-segment elevation myocardial infarction, or ST-segment elevation myocardial infarction, and underwent percutaneous coronary intervention. Enrolled patients were randomly assigned, via a web-based system by computer-generated block randomisation, to either the 6-month DAPT group or to the 12-month or longer DAPT group, with stratification by site, clinical presentation, and diabetes. Assessors were masked to treatment allocation. The primary endpoint was a composite of all-cause death, myocardial infarction, or stroke at 18 months after the index procedure in the intention-to-treat population. Secondary endpoints were the individual components of the primary endpoint; definite or probable stent thrombosis as defined by the Academic Research Consortium; and Bleeding Academic Research Consortium (BARC) type 2-5 bleeding at 18 months after the index procedure. The primary endpoint was also analysed per protocol. This trial is registered with ClinicalTrials.gov, number NCT01701453.

FINDINGS: Between Sept 5, 2012, and Dec 31, 2015, we randomly assigned 2712 patients; 1357 to the 6-month DAPT group and 1355 to the 12-month or longer DAPT group. Clopidogrel was used as a P2Y12 inhibitor for DAPT in 1082 (79·7%) patients in the 6-month DAPT group and in 1109 (81·8%) patients in the 12-month or longer DAPT group. The primary endpoint occurred in 63 patients in the 6-month DAPT group and in 56 patients in the 12-month or longer DAPT group (cumulative event rate 4·7% vs 4·2%; absolute risk difference 0·5%; upper limit of one-sided 95% CI 1·8%; pnon-inferiority=0·03 with a predefined non-inferiority margin of 2·0%). Although all-cause mortality did not differ significantly between the 6-month DAPT group and the 12-month or longer DAPT group (35 [2·6%] patients vs 39 [2·9%]; hazard ratio [HR] 0·90 [95% CI 0·57-1·42]; p=0·90) and neither did stroke (11 [0·8%] patients vs 12 [0·9%]; 0·92 [0·41-2·08]; p=0·84), myocardial infarction occurred more frequently in the 6-month DAPT group than in the 12-month or longer DAPT group (24 [1·8%] patients vs ten [0·8%]; 2·41 [1·15-5·05]; p=0·02). 15 (1·1%) patients had stent thrombosis in the 6-month DAPT group compared with ten (0·7%) in the 12-month or longer DAPT group (HR 1·50 [95% CI 0·68-3·35]; p=0·32). The rate of BARC type 2-5 bleeding was 2·7% (35 patients) in the 6-month DAPT group and 3·9% (51 patients) in the 12-month or longer DAPT group (HR 0·69 [95% CI 0·45-1·05]; p=0·09). Results from the per-protocol analysis were similar to those from the intention-to-treat analysis.

INTERPRETATION: The increased risk of myocardial infarction with 6-month DAPT and the wide non-inferiority margin prevent us from concluding that short-term DAPT is safe in patients with acute coronary syndrome undergoing percutaneous coronary intervention with current-generation DES. Prolonged DAPT in patients with acute coronary syndrome without excessive risk of bleeding should remain the standard of care.

FUNDING: Abbott Vascular Korea, Medtronic Vascular Korea, Biosensors Inc, and Dong-A ST.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Hahn JY, Song YB, Oh JH, et al. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. Lancet. 2018. PMID: 29544699. doi:10.1016/S0140-6736(18)30493-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。